StockNews.com upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) from a sell rating to a hold rating in a research report report published on Tuesday.
Several other research firms also recently weighed in on RARE. Canaccord Genuity Group reissued a buy rating and issued a $90.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 18th. Cowen reduced their price target on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a research report on Thursday, November 3rd. Robert W. Baird upgraded Ultragenyx Pharmaceutical from a neutral rating to an outperform rating and lowered their price objective for the company from $63.00 to $50.00 in a research report on Thursday, November 3rd. Cowen cut their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $65.00 in a report on Thursday, November 3rd. Finally, Credit Suisse Group lowered their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $96.00 and set an outperform rating for the company in a report on Thursday, November 3rd. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of Moderate Buy and an average target price of $91.69.
Get Ultragenyx Pharmaceutical alerts:Ultragenyx Pharmaceutical Stock Performance
RARE stock opened at $47.64 on Tuesday. The company has a market capitalization of $3.34 billion, a PE ratio of -4.89 and a beta of 0.96. Ultragenyx Pharmaceutical has a one year low of $33.36 and a one year high of $85.53. The company's 50 day moving average price is $43.49 and its two-hundred day moving average price is $43.43.
Insider Buying and Selling at Ultragenyx Pharmaceutical
In related news, CAO Theodore Alan Huizenga sold 2,031 shares of the company's stock in a transaction on Wednesday, December 21st. The stock was sold at an average price of $43.96, for a total value of $89,282.76. Following the sale, the chief accounting officer now directly owns 16,197 shares of the company's stock, valued at $712,020.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 6.70% of the company's stock.Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Hedge funds and other institutional investors have recently bought and sold shares of the business. Signaturefd LLC boosted its position in shares of Ultragenyx Pharmaceutical by 151.0% in the 3rd quarter. Signaturefd LLC now owns 600 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 361 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Ultragenyx Pharmaceutical during the third quarter valued at $27,000. Lazard Asset Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 36.6% in the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 240 shares in the last quarter. High Net Worth Advisory Group LLC grew its stake in shares of Ultragenyx Pharmaceutical by 650.0% in the third quarter. High Net Worth Advisory Group LLC now owns 1,500 shares of the biopharmaceutical company's stock worth $62,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Harbor Capital Advisors Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 26.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,264 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 469 shares during the last quarter. Hedge funds and other institutional investors own 93.17% of the company's stock.
About Ultragenyx Pharmaceutical
(Get Rating)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Featured Articles
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- 3 Hot Stocks The Analysts Are Buying
- Hertz Global Holding Could Be A Comfortable Ride In 2023
- Two Billionaires Are Rigging the Market. Here's How to Fight Back
- Should Investors Buy or Sell the Vaccinex Patent News?
- Take-Two Interactive Or Activision Blizzard: An Obvious Choice?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.